The present invention relates to an RGD motif-containing peptide or a fragment thereof, which is used to effectively treat burns and glaucoma, obtain an excellent effect of alleviating skin wrinkles, and is effective in the promotion of hair restoration and hair growth as well as the prevention of hair loss. Therefore, the motif-containing peptide or the fragment thereof can be utilized for a cosmetic composition and a pharmaceutical composition.

Variants of the transglutaminase enzyme of Streptomyces mobaraensis are provided. The disclosed variants exhibit at least about 2-fold increased enzymatic activity versus the wild-type enzyme. Methods and compositions are provided for biocidal applications of use and for covalently binding small organic molecules to a protein or material of interest. Methods are provided for increasing the self-life of products, such as personal care, household and industrial products, by incorporating an effective amount of the disclosed variant enzymes into the product. The transglutaminase variants may also be used to covalently bind functional ingredients, such as UV-blocking molecules, dyes, or pigments to proteins. The transglutaminase enzymes and functional ingredients may be incorporated into a cosmetic formulation for modifying skin, hair, or nail proteins or skin-derived proteins, such as collagen, keratin, and/or elastin.

Variants of the transglutaminase enzyme of Streptomyces mobaraensis are provided. The disclosed variants exhibit at least about 2-fold increased enzymatic activity versus the wild-type enzyme. Methods and compositions are provided for biocidal applications of use and for covalently binding small organic molecules to a protein or material of interest. Methods are provided for increasing the self-life of products, such as personal care, household and industrial products, by incorporating an effective amount of the disclosed variant enzymes into the product. The transglutaminase variants may also be used to covalently bind functional ingredients, such as UV-blocking molecules, dyes, or pigments to proteins. The transglutaminase enzymes and functional ingredients may be incorporated into a cosmetic formulation for modifying skin, hair, or nail proteins or skin-derived proteins, such as collagen, keratin, and/or elastin.

Novel lysozyme enzymes from the genus of Rasamsonia.

Novel lysozyme enzymes from the genus of Rasamsonia.

The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

The present invention relates more specifically to a cosmetic treatment method intended in particular to improve the appearance of the skin and/or hair comprising the simultaneous and/or sequential administration: a) of at least one cytochrome C oxidase substrate and/or of at least one agent which increases the expression of the said substrate; and b) of at least one light radiation exhibiting at least one predominant wavelength which activates cytochrome C oxidase. In particular, the said light radiation exhibits at least one predominant wavelength which activates cytochrome C oxidase ranging from 550 to 1000 nm, in particular from 550 to 800 nm, preferably from 620 to 700 nm and more preferably still from 640 to 680 nm and is preferably used at a dose ranging from 0.01 to 200 J/cm.sup.2, preferably from 0.1 to 30 J/cm.sup.2, more preferably from 1 to 30 J/cm.sup.2, indeed even from 5 to 30 J/cm.sup.2. The invention also relates to a composition comprising at least one cytochrome C oxidase substrate and/or one agent which increases the expression of the said substrate and at least one compound emitting and/or filtering, in particular under exposure to light, a light radiation exhibiting at least one predominant wavelength which activates cytochrome C oxidase, and to a kit comprising at least one composition comprising at least one cytochrome C oxidase substrate and/or one agent which increases the expression of the said substrate and one device and/or one compound emitting/filtering a light radiation exhibiting at least one predominant wavelength which activates cytochrome C oxidase.

The present invention relates more specifically to a cosmetic treatment method intended in particular to improve the appearance of the skin and/or hair comprising the simultaneous and/or sequential administration: a) of at least one cytochrome C oxidase substrate and/or of at least one agent which increases the expression of the said substrate; and b) of at least one light radiation exhibiting at least one predominant wavelength which activates cytochrome C oxidase. In particular, the said light radiation exhibits at least one predominant wavelength which activates cytochrome C oxidase ranging from 550 to 1000 nm, in particular from 550 to 800 nm, preferably from 620 to 700 nm and more preferably still from 640 to 680 nm and is preferably used at a dose ranging from 0.01 to 200 J/cm.sup.2, preferably from 0.1 to 30 J/cm.sup.2, more preferably from 1 to 30 J/cm.sup.2, indeed even from 5 to 30 J/cm.sup.2. The invention also relates to a composition comprising at least one cytochrome C oxidase substrate and/or one agent which increases the expression of the said substrate and at least one compound emitting and/or filtering, in particular under exposure to light, a light radiation exhibiting at least one predominant wavelength which activates cytochrome C oxidase, and to a kit comprising at least one composition comprising at least one cytochrome C oxidase substrate and/or one agent which increases the expression of the said substrate and one device and/or one compound emitting/filtering a light radiation exhibiting at least one predominant wavelength which activates cytochrome C oxidase.

The present invention provides a delivery system for the treatment and/or prevention of infectious pathological changes, including compositions comprising polyhexanide, various pharmaceutical formulations, and processes for using these formulations in oral treatment modalities.